Comparison of three molecular methods to detect mutations in <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i> and <i>PIK3CA</i> in metastatic colorectal cancer (mCRC).
Cristina Santos(Leiden University Medical Center), Ramón Salazar(Institut Català d'Oncologia), Daniel Azuara(Bellvitge University Hospital), Bartomeu Massutí(Universitat de Miguel Hernández d'Elx), Mar Varela(Bellvitge University Hospital), Josep Tabernero(Deaconess Hospital), Elena Élez(Vall d'Hebron Hospital Universitari), Gabriel Capellá(Institut Català d'Oncologia), José Luís Manzano(Badalona Serveis Assistencials), Xavier Sanjuán(Bellvitge University Hospital), Ferrán Losa, Rocio García‐Carbonero(Research Institute Hospital 12 de Octubre), Pilar Alfonso, Enrique Aranda(Instituto Maimónides de Investigación Biomédica de Córdoba), Alfredo Carrato(Hospital General Universitario de Elche), Valentín Navarro-Perez(Institut d'Investigació Biomédica de Bellvitge), Manuel Valladares(American Society of Clinical Oncology), Clara Montagut(Hospital Del Mar), María Auxiliadora Gómez‐España(Instituto de Salud Carlos III), J.M. Viéitez(Hospital Universitario Central de Asturias)
Cited by 1
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k